Denali Therapeutics Inc. $DNLI Shares Purchased by Defilade Capital Management L.P.

Defilade Capital Management L.P. boosted its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 107.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,359,969 shares of the company’s stock after acquiring an additional 703,256 shares during the quarter. Denali Therapeutics accounts for approximately 3.7% of Defilade Capital Management L.P.’s investment portfolio, making the stock its 12th biggest position. Defilade Capital Management L.P.’s holdings in Denali Therapeutics were worth $26,111,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of DNLI. State of Wyoming increased its stake in Denali Therapeutics by 24.7% during the fourth quarter. State of Wyoming now owns 2,686 shares of the company’s stock worth $44,000 after purchasing an additional 532 shares during the period. Intrust Bank NA boosted its stake in shares of Denali Therapeutics by 5.6% in the fourth quarter. Intrust Bank NA now owns 11,164 shares of the company’s stock valued at $184,000 after purchasing an additional 589 shares during the period. ADAR1 Capital Management LLC grew its holdings in shares of Denali Therapeutics by 1.2% in the fourth quarter. ADAR1 Capital Management LLC now owns 52,116 shares of the company’s stock valued at $860,000 after purchasing an additional 600 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Denali Therapeutics by 8.7% in the first quarter. PNC Financial Services Group Inc. now owns 9,220 shares of the company’s stock valued at $177,000 after purchasing an additional 739 shares in the last quarter. Finally, Pier 88 Investment Partners LLC increased its stake in Denali Therapeutics by 1.1% during the 4th quarter. Pier 88 Investment Partners LLC now owns 68,200 shares of the company’s stock worth $1,126,000 after buying an additional 760 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on DNLI. Wedbush reiterated an “outperform” rating and set a $26.00 target price on shares of Denali Therapeutics in a report on Monday, July 13th. JPMorgan Chase & Co. initiated coverage on Denali Therapeutics in a research report on Monday, July 13th. They set an “overweight” rating and a $29.00 price objective on the stock. BTIG Research reiterated a “buy” rating and issued a $39.00 price objective on shares of Denali Therapeutics in a research note on Monday, May 11th. Sanford C. Bernstein reiterated a “hold” rating on shares of Denali Therapeutics in a report on Monday, June 22nd. Finally, Morgan Stanley boosted their target price on Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Thirteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $35.17.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $23.02 on Monday. Denali Therapeutics Inc. has a fifty-two week low of $12.58 and a fifty-two week high of $27.30. The firm’s 50 day moving average price is $23.12 and its 200 day moving average price is $21.09. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01. The stock has a market cap of $3.65 billion, a price-to-earnings ratio of -7.99 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same quarter last year, the firm posted ($0.78) EPS. As a group, equities research analysts predict that Denali Therapeutics Inc. will post -2.73 earnings per share for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.